| Literature DB >> 25648693 |
Xiang Lei1, Jing Chen1, Jingtian Ren2, Yan Li1, Jingbo Zhai1, Wei Mu3, Li Zhang3, Wenke Zheng1, Guihua Tian4, Hongcai Shang5.
Abstract
Objective. To summarize the characteristics and analysis of relevant factors and to give references for prevention and further study of liver damage associated with Polygonum multiflorum Thunb. (HSW), we provide a systematic review of case reports and case series about liver damage associated with HSW. Methods. An extensive search of 6 medical databases was performed up to June 2014. Case reports and case series involving liver damage associated with HSW were included. Results. This review covers a total of 450 cases in 76 articles. HSW types included raw and processed HSW decoction pieces and many Chinese patent medicines that contain HSW. Symptoms of liver damage occur mostly a month or so after taking the medicine, mainly including jaundice, fatigue, anorexia, and yellow or tawny urine. Of the 450 patients, two cases who received liver transplantation and seven who died, the remaining 441 cases recovered or had liver function improvement after discontinuing HSW products and conservative care. Conclusion. HSW causes liver toxicity and may cause liver damage in different degrees and even lead to death; most of them are much related to long-term and overdose of drugs. Liver damage associated with HSW is reversible, and, after active treatment, the majority can be cured. People should be alert to liver damage when taking HSW preparations.Entities:
Year: 2015 PMID: 25648693 PMCID: PMC4306360 DOI: 10.1155/2015/459749
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Raw HSW.
Figure 2Processed HSW.
Patient details recorded from published case reports.
| Reference | Age/gender | Reasons for medication | HSW type | Administration and dosage | Duration of intake, day | Hospitalization, day | Outcome | Rechallenge? |
|---|---|---|---|---|---|---|---|---|
|
Liu et al. [ | 20/F | Grey hair | HSW | OAP, 15 g | 42 | 10 | Recovery | NA |
|
Miao and Yun [ | 52/F | Health care | P. HSW | OAP, 5 g | 20 | 14 | Recovery | NA |
| 61/F | Hyperlipidemia | R. HSW | SIW, 5 g | 180 | 12 | Recovery | NA | |
| Zhao [ | 39/M | Grey hair | Jing-Wu-Pian | Oral, 3 × 6 tablets | 60 | 18 | Recovery | NA |
| Tan [ | 48/F | NA | P. HSW | uNA, 10 g | 40 | 30 | Recovery | NA |
| Liu et al. [ | 37/M | Vitiligo | P. HSW | OAP, 10 g | 30 | 35 | Recovery | NA |
| Gao et al. [ | 14/F | Vitiligo | P. HSW | Decoction, NA | 38 | 15 | Recovery | NA |
| Baňárová et al. [ | 33/F | NA | SWW | Oral, NA | 60 | NA | Recovery | NA |
| Gao [ | 45/M | Hair loss | P. HSW | OAP, NA | 90 | 21 | Recovery | NA |
| Kui and Chen [ | 43/F | Grey hair | HSW | OAP, 8–10 g | 60 | 30 | Recovery | NA |
|
Shao and Li [ | 50/M | Grey hair | HSW | OAP, NA | 60 | 30 | Recovery | NA |
| 40/F | Health care | R. HSW | Decoction, 10–20 g | 60 | 50 | Recovery | NA | |
| Hu et al. [ | 36/M | Chronic nephritis | P. HSW | OAP, 15 g | 30 | 37 | Recovery | NA |
| Zhen and Zeng [ | 52/F | Grey hair | P. HSW | OAP, NA | 14 | 30 | Recovery | NA |
|
Li and Zhang [ | 50/F | Grey hair | R. HSW | OAP, 2 g | 60 | 15 | Recovery | NA |
| 28/F | Hair loss | R. HSW | OAP, 3 g | 75 | 12 | Recovery | NA | |
| Chen et al. [ | 57/M | Grey hair | R. HSW | NA | 1 | 20 | Recovery | NA |
| Liu et al. [ | 56/F | Grey hair | Yishen wufa | Oral, 2 × 10 mL | 120 | 21 | Recovery | NA |
|
Sun [ | 39/F | Allergic rhinitis | R. HSW | Decoction, 15–20 g | 30 | 28 | Recovery | NA |
| 72/F | Health care | R. HSW | Decoction, 10–20 g | 60 | 42 | Recovery | NA | |
| Cao et al. [ | 28/M | Grey hair | P. HSW | NA, 10 pieces | 90 | 42 | Recovery | NA |
| Liu et al. [ | 26/M | Hair loss | Yangxue shengfa | Oral, 2 × 4 capsules | 60 | 30 | Recovery | NA |
| Yan [ | 28/M | Hair loss | HSW | Decoction, 4 g | 90 | 28 | Recovery | NA |
| Wu and Niu [ | 47/F | Hair loss | Yishen wufa | Oral, 3 × 10 ml | 20 | 14 | Recovery | NA |
| Liu et al. [ | 50/F | Hair loss | SWW | Oral, NA | 7 | 25 | Recovery | NA |
|
Chen et al. [ | 46/F | Health care | HSW tea | Oral, 1-2 g | 60 | 25 | Recovery | NA |
| 57/M | Health care | HSW tea | Oral, 1-2 g | 20 | 15 | Recovery | NA | |
| Yun et al. [ | 51/F | Grey hair | SWW | Oral, 2 × 6 g | 180 | 18 | Recovery | NA |
| Furukawa et al. [ | 53/F | NA | SWP | NA | 240 | 60 | Recovery | NA |
| Yan et al. [ | 54/F | Grey hair | HSW | OAP, 2 × 10 g | 60 | 35 | Recovery | NA |
| He [ | 31/F | Constipation | HSW | Oral, NA | 15 | 10 | Recovery | NA |
| Chen [ | 38/F | Grey hair | HSW | OAP, NA | 120 | 63 | Recovery | NA |
| Cho et al. [ | 34/M | NA | HSW | HSW tea (liquor), NA | 30 (4) | 34 | improved | NA |
|
Wang et al. [ | 34/M | Health care | R. HSW | SIW, NA | 20 | 20 | Recovery | NA |
| 46/M | Health care | R. HSW | SIW, NA | 10 | 27 | Recovery | NA | |
| 49/F | Health care | R. HSW | SIW, NA | 5 | 27 | Recovery | NA | |
| Zhu [ | 36/M | Hair loss | R. HSW | SIW, NA | 30 | 30 | Recovery | NA |
|
Yang and Li [ | 38/M | Grey hair | HSW | Decoction, 30 g | Once a week (3w) | NA | Recovery | NA |
| 51/M | Sequelae of stroke | HSW | Decoction, 15 g | 15 | NA | Recovery | NA | |
| Laird et al. [ | 35/M | Thinning hair | NuHair | Oral, NA | NA | 120 | Recovery | NA |
|
Yang and Dong [ | 54/M | Hair loss | SWP | Oral, 3 × 6 tablets | 40 | 17 | Recovery | NA |
| 26/M | Grey hair | SWP | Oral, 3 × 6 tablets | 30 | 59 | Recovery | Yes | |
| Fu and Yu [ | 32/F | Infertility | P. HSW | Decoction, NA | 18 | Untreated | Recovery | NA |
| Zhao [ | 17/M | Grey hair | SWW | Oral, 3 × 6 tablets | 40 | 90 | Recovery | Yes |
|
Li [ | 65/M | Dizziness, tinnitus | HSW | SIW, 30–50 ml | 20 | 30 | Recovery | Yes |
| 38/M | Grey hair | SWP | Oral, 3 × 6 tablets | 30 | 20 | Recovery | NA | |
| Cárdenas et al. [ | 28/F | Hair loss | Shen-Min | Oral, 2 tablets | 56 | 6 | Recovery | NA |
| Han [ | 42/F | Grey hair | HSW | OAP, 10 g | 90 | 30 | Recovery | Yes |
| Yang [ | 35/M | Grey hair | P. HSW | Decoction, 30 g | 45 | 50 | Recovery | NA |
| Panis et al. [ | 5/F | NA | SWP | Oral, 3 tablets | 120 | 30 | Recovery | Yes |
| Chen et al. [ | 20/F | Grey hair | HSW | OAP, NA | 20 | 40 | Recovery | NA |
| Huo and Ling [ | 28/M | Hair loss | SWP + Yangxue shengfa | Oral, 3 × 5 tablets and 2 × 4 capsules | 60 | 18 | Recovery | Yes |
| Mazzanti et al. [ | 78/M | Chronic prostatitis | SWP | Oral, RD | 30 | NA | Recovery | NA |
|
Shao [ | 46/F | Hair loss | R. HSW | Decoction, NA | 6 | 30 | Recovery | Yes |
| 45/M | Grey hair, hair loss | R. HSW | Decoction, 100 g | NA | 30 | Recovery | Yes | |
| Leng [ | 15/F | Grey hair | HSW | Decoction, 15 g | 30 | NA | Recovery | NA |
| Dai and Li [ | 18/F | Grey hair | SWP | Oral, NA | 90 | 90 | Recovery | NA |
| Yuan [ | 66/F | Constipation | HSW ointment | Oral, NA | 7 | 30 | Recovery | Yes |
| Sun [ | 20/F | Neurasthenia | SWP + Liuwei Dihuang Wan | Oral, 3 × 6 tablets and 2 × 9 g | 3 | 10 | Recovery | Yes |
| Yang [ | 17/M | Grey hair | SWP | Oral, NA | 14 | 29 | Recovery | Yes |
| Park et al. [ | 46/F | Grey hair | SWP | Oral, RD | 14 | 30 | Recovery | NA |
| Sheng [ | 38/F | Grey hair | HSW | Oral, NA | 6 | NA | Recovery | Yes |
|
Li et al. [ | 58/F | Dizziness | HSW | Decoction, 30 g | 7 | 15 | Recovery | Yes |
| 49/M | Hypertension | HSW | SIW, 15 g | 10 | 20 | Recovery | Yes | |
| Fan and Zhou [ | 26/M | Grey hair | SWP | Oral, 3 × 6 tablets | 30 | 59 | Recovery | Yes |
| Li [ | 17/M | Grey hair | SWP | Oral, 3 × 5 tablets | 20 | 60 | Recovery | Yes |
| Ye [ | 30/M | Grey hair | HSW | Decoction, 50 g | 2 | 94 | Recovery | Yes |
| Zhang [ | 36/F | NA | SWP | Oral, 10 ml | 15 | 15 | Recovery | Yes |
| Niu [ | 28/M | Grey hair | SWP | Oral, 3 × 5 tablets | 10 | 60 | Recovery | Yes |
|
He and Zhen [ | 19/F | Grey hair | SWP | Oral, NA | NA | 30 | Recovery | Yes |
| 27/F | Grey hair | SWP | Oral, NA | NA | NA | Recovery | Yes | |
| But et al. [ | 31, F | Dizziness | SWP | Oral, RD | Several weeks | 21 | Recovery | Yes |
SWP: Shou-Wu-Pian; SWW: Shou-Wu-Wan; OAP: oral administration of powder; SIW: soaked in water to drink; P. HSW: processed HSW; R. HSW: raw HSW; HSW: unclear whether it was processed; RD: recommended dosages; NA: not available.
Characteristics of included case series.
| Reference | Number of cases | Gender (F/M) | Age (a) | Duration of intake, day | Type of liver injury (number) | Outcome |
|---|---|---|---|---|---|---|
| Dong et al. [ | 18 | 5/13 | 18–63 | 1–120 | H (18) | 18 recoveries |
| Lian et al. [ | 52 | 22/30 | 22–69 | 5–120 | H (30); C (9); M (13) | 52 recoveries |
| Zhang et al. [ | 13 | 11/2 | 35–66 | 4–15 | H (6); C (4); M (3) | 12 recoveries; 1 LT |
| Zhang et al. [ | 36 | 13/23 | 24–73 | NA | H (21); C (2); M (13) | 33 recoveries; 1 cirrhosis; 2 deaths |
| Ding [ | 65 | 45/20 | 34–71 | 7–90 | NA | 64 recoveries; 1 death |
| Guo [ | 15 | 8/7 | 18–57 | 7–56 | H (8); C (3); M (4) | 15 recoveries |
| Xie et al. [ | 10 | 3/7 | 46.1 ± 10.2 | 30–105 | H (5); C (4); M (1); | 9 recoveries; 1 death |
| Song [ | 26 | 12/14 | 38–71 | 9–93 | NA | 26 recoveries |
| Wang [ | 20 | 7/13 | 34–67 | NA | NA | 20 recoveries |
| Jung et al. [ | 25 | 7/18 | 24–65 | 1–180 | H (18); M (7) | 23 recoveries; 1 LT; 1 death |
| Chen et al. [ | 12 | 5/7 | 20–70 | 15–90 | H (4); C (4); M (4) | 12 recoveries |
| Liu and Li [ | 7 | 5/2 | 31–64 | 60–180 | NA | 7 recoveries |
| Liu [ | 9 | 3/6 | 34–68 | NA | NA | 9 recoveries |
| Xu et al. [ | 40 | 24/16 | 45.2 | 9–168 | H (22); C (8); M (10) | 38 recoveries; 2 deaths |
| Yang et al. [ | 13 | 8/5 | 32–68 | 7–30 | NA | 13 recoveries |
| Zhou and Qiu [ | 11 | 5/6 | 34–58 | NA | NA | 11 recoveries |
| Zhang et al. [ | 6 | 3/3 | 24–50 | 4–24 w | NA | 6 recoveries |
NA: not available; H: hepatocellular; C: cholestatic; M: mixed; LT: liver transplantation.
Use reasons of case reports.
| Disease originally treated | Patients (number) |
|---|---|
| Gray hair, hair loss | 43 (59.7%) |
| Health care | 8 (11.1%) |
| Dizziness | 3 (4.2%) |
| Vitiligo | 2 (2.8%) |
| Constipation | 2 (2.8%) |
| Othersa | 8 (11.1%) |
| Unknown | 6 (8.3%) |
|
| |
| Total | 72 (100%) |
aIncluding infertility, hypertension, allergic rhinitis, hyperlipidemia, cerebral infarction sequelae, chronic nephritis and neurasthenia, and chronic prostatitis.
The classification of the drug of case reports.
| Dosage forms | Patients (number) |
|---|---|
| Chinese patent medicine | |
| Shou-Wu-Pian | 17 (23.61%) |
| Shou-Wu-Wan | 4 (5.56%) |
| Yishen wufa | 2 (2.78%) |
| Othersb | 5 (6.94%) |
| Decoction pieces | |
| R. HSW | 13 (18.06%) |
| P. HSW | 10 (13.89%) |
| Unknown | 21 (29.17%) |
|
| |
| Total | 72 (100%) |
bIncluding Huolisu Koufuye, Jing-Wu-Pian, NuHair, Shen-Min, and Yangxue shengfa capsules.
The duration of taking HSW of case reports.
| Duration (day) | Patients (number) |
|---|---|
| <10 | 10 (13.89%) |
| 10–30 | 27 (37.50%) |
| 31–60 | 19 (26.39%) |
| >60 | 12 (16.67%) |
| Unknown | 4 (5.56%) |
|
| |
| Total | 72 (100%) |
The length of hospitalization of case reports.
| Hospitalization (d) | Patients (number) |
|---|---|
| <15 | 8 (11.1%) |
| 15–30 | 37 (51.4%) |
| 31–60 | 14 (19.4%) |
| >60 | 5 (6.9%) |
| Unknown | 8 (11.1%) |
|
| |
| Total | 72 (100%) |